These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 36345412)

  • 1. Outlook of various diagnostics and nanodiagnostic techniques for COVID-19.
    Preethi M; Roy L; Lahkar S; Borse V
    Biosens Bioelectron X; 2022 Dec; 12():100276. PubMed ID: 36345412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lab-on-a-Disc for Point-of-Care Infection Diagnostics.
    Sunkara V; Kumar S; Sabaté Del Río J; Kim I; Cho YK
    Acc Chem Res; 2021 Oct; 54(19):3643-3655. PubMed ID: 34516092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State-of-the-Art Smart and Intelligent Nanobiosensors for SARS-CoV-2 Diagnosis.
    Thapa S; Singh KR; Verma R; Singh J; Singh RP
    Biosensors (Basel); 2022 Aug; 12(8):. PubMed ID: 36005033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Green chemistry and coronavirus.
    Ahmadi S; Rabiee N; Fatahi Y; Hooshmand SE; Bagherzadeh M; Rabiee M; Jajarmi V; Dinarvand R; Habibzadeh S; Saeb MR; Varma RS; Shokouhimehr M; Hamblin MR
    Sustain Chem Pharm; 2021 Jun; 21():100415. PubMed ID: 33686371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects of nanomaterials-enabled biosensors for COVID-19 detection.
    Srivastava M; Srivastava N; Mishra PK; Malhotra BD
    Sci Total Environ; 2021 Feb; 754():142363. PubMed ID: 33254928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Commercialized diagnostic technologies to combat SARS-CoV2: Advantages and disadvantages.
    Pérez-López B; Mir M
    Talanta; 2021 Apr; 225():121898. PubMed ID: 33592692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobiosensors as new diagnostic tools for SARS, MERS and COVID-19: from past to perspectives.
    Antiochia R
    Mikrochim Acta; 2020 Nov; 187(12):639. PubMed ID: 33151419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deciphering the role of nanostructured materials in the point-of-care diagnostics for COVID-19: a comprehensive review.
    Krishnan S; Dusane A; Morajkar R; Venkat A; Vernekar AA
    J Mater Chem B; 2021 Aug; 9(30):5967-5981. PubMed ID: 34254626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanobiosensors for the Detection of Novel Coronavirus 2019-nCoV and Other Pandemic/Epidemic Respiratory Viruses: A Review.
    Alhalaili B; Popescu IN; Kamoun O; Alzubi F; Alawadhia S; Vidu R
    Sensors (Basel); 2020 Nov; 20(22):. PubMed ID: 33218097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology-Based Strategies for Effective and Rapid Detection of SARS-CoV-2.
    Moabelo KL; Martin DR; Fadaka AO; Sibuyi NRS; Meyer M; Madiehe AM
    Materials (Basel); 2021 Dec; 14(24):. PubMed ID: 34947447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory-Based Resources for COVID-19 Diagnostics: Traditional Tools and Novel Technologies. A Perspective of Personalized Medicine.
    Andryukov BG; Besednova NN; Kuznetsova TA; Fedyanina LN
    J Pers Med; 2021 Jan; 11(1):. PubMed ID: 33451039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances in nanomaterials based biosensors for point of care (PoC) diagnosis of Covid-19 - A minireview.
    Gowri A; Ashwin Kumar N; Suresh Anand BS
    Trends Analyt Chem; 2021 Apr; 137():116205. PubMed ID: 33531721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Point of care testing: The impact of nanotechnology.
    Syedmoradi L; Daneshpour M; Alvandipour M; Gomez FA; Hajghassem H; Omidfar K
    Biosens Bioelectron; 2017 Jan; 87():373-387. PubMed ID: 27589400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of point-of-care diagnostic devices in the Indian healthcare system with an update on COVID-19 pandemic.
    Konwar AN; Borse V
    Sens Int; 2020; 1():100015. PubMed ID: 34766037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid diagnostics of coronavirus disease 2019 in early stages using nanobiosensors: Challenges and opportunities.
    Sharifi M; Hasan A; Haghighat S; Taghizadeh A; Attar F; Bloukh SH; Edis Z; Xue M; Khan S; Falahati M
    Talanta; 2021 Feb; 223(Pt 1):121704. PubMed ID: 33303154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Point-of-Care Biosensors for COVID-19.
    Choi JR
    Front Chem; 2020; 8():517. PubMed ID: 32574316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point-of-Care Diagnostic Tools for Surveillance of SARS-CoV-2 Infections.
    Sakthivel D; Delgado-Diaz D; McArthur L; Hopper W; Richards JS; Narh CA
    Front Public Health; 2021; 9():766871. PubMed ID: 34900912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current state of diagnostic, screening and surveillance testing methods for COVID-19 from an analytical chemistry point of view.
    Martín J; Tena N; Asuero AG
    Microchem J; 2021 Aug; 167():106305. PubMed ID: 33897053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New and developing diagnostic platforms for COVID-19: A systematic review.
    Chauhan N; Soni S; Gupta A; Jain U
    Expert Rev Mol Diagn; 2020 Sep; 20(9):971-983. PubMed ID: 32896179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Point-of-care diagnostics for infectious diseases: From methods to devices.
    Wang C; Liu M; Wang Z; Li S; Deng Y; He N
    Nano Today; 2021 Apr; 37():101092. PubMed ID: 33584847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.